Cargando…
Residual Tumor Cells That Drive Disease Relapse after Chemotherapy Do Not Have Enhanced Tumor Initiating Capacity
Although chemotherapy is used to treat most advanced solid tumors, recurrent disease is still the major cause of cancer-related mortality. Cancer stem cells (CSCs) have been the focus of intense research in recent years because they provide a possible explanation for disease relapse. However, the pr...
Autores principales: | Hegde, Ganapati V., de la Cruz, Cecile, Eastham-Anderson, Jeffrey, Zheng, Yanyan, Sweet-Cordero, E. Alejandro, Jackson, Erica L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480356/ https://www.ncbi.nlm.nih.gov/pubmed/23115623 http://dx.doi.org/10.1371/journal.pone.0045647 |
Ejemplares similares
-
New insights into tumor suppressors
por: Marques, Michelle, et al.
Publicado: (2008) -
Tie2 Receptor in Tumor-Infiltrating Macrophages Is Dispensable for Tumor Angiogenesis and Tumor Relapse after Chemotherapy
por: Jakab, Moritz, et al.
Publicado: (2022) -
Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids
por: Song, Hanbing, et al.
Publicado: (2022) -
Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles
por: Kim, Se Ik, et al.
Publicado: (2020) -
Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease
por: Mahmudi, Hossein, et al.
Publicado: (2022)